The Lancet Commission on prostate cancer: planning for the surge in casesNicholas D. James, Liping Xie, Ian F. Tannock et al.|The Lancet|2024Cited by 694
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E. Langley, Mahesh Parmar, Matthew Nankivell et al.|The Lancet|2021Cited by 49